NYSE: $ABBV
A New Milestone in Crohn’s Disease Management
For adults living with moderately to severely active Crohn’s disease, there is a significant new development in treatment accessibility. The U.S. Food and Drug Administration (FDA) has officially approved a subcutaneous (SC) induction regimen for AbbVie’s Skyrizi (risankizumab-rzaa).
What This Means for Patients
Previously, patients often required intravenous (IV) infusions to begin their treatment journey. This new approval allows patients to receive their induction treatment through a subcutaneous injection, offering more flexibility in how they start their therapy.
Key takeaways regarding the update:
- Simplified Administration: The subcutaneous induction regimen provides an alternative for patients who may prefer or require non-IV administration.
- Targeted Treatment: Skyrizi remains a selective IL-23 inhibitor, designed to target the underlying inflammation associated with Crohn’s disease.
- Expanded Access: This approval is a critical step for AbbVie in providing diverse therapeutic options for those managing this chronic condition.
Understanding Crohn’s Disease Treatment
Crohn’s disease is a complex, chronic condition that requires consistent management. By offering an injectable induction option, healthcare providers now have a broader toolkit to tailor treatment plans to the specific needs and lifestyles of their patients. As always, patients should consult with their gastroenterologist to discuss whether this regimen is appropriate for their specific health history and treatment goals.
Source: Read More